US Stock MarketDetailed Quotes
ROIV Roivant Sciences
- 12.710
- +0.020+0.16%
Close Nov 29 13:00 ET
- 12.700
- -0.010-0.08%
Post 16:55 ET
9.25BMarket Cap2.18P/E (TTM)
12.825High12.570Low2.44MVolume12.620Open12.690Pre Close31.06MTurnover0.66%Turnover Ratio2.43P/E (Static)727.95MShares13.05552wk High1.80P/B4.72BFloat Cap9.48052wk Low--Dividend TTM371.75MShs Float16.760Historical High--Div YieldTTM2.01%Amplitude2.520Historical Low12.728Avg Price1Lot Size
About Roivant Sciences Company
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Company Profile
SymbolROIV
Company NameRoivant Sciences
Listing DateDec 14, 2020
Founded2021
CEOMr. Matthew Gline
MarketNASDAQ
Employees908
Fiscal Year Ends03-31
Address50 Broadway,7th Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeSW1H 0BD
Phone44-207-400-3347
Websitehttp://www.roivant.com
Company Executives
- Name
- Position
- Salary
- Matthew Gline
- Chief Executive Officer and Director
- 738.19K
- Dr. Eric Venker, M.D.,Pharm.D.
- President and Chief Operating Officer
- --
- Rakhi Kumar
- Chief Accounting Officer
- 4.33M
- Richard Pulik
- Chief Financial Officer
- 5.15M
- Dr. Mayukh Sukhatme
- President, Chief Investment Officer and Director
- 574.56K
- Ilan Oren
- Chairman of the Board
- 488.49K
- Meghan M. Fitzgerald, Ph.
- Independent Director
- 941.68K
- James C. Momtazee
- Independent Director
- 459.24K
- Melissa B. Epperly
- Independent Director
- 444.24K
- Daniel Gold
- Independent Director
- 449.24K
- Keith Manchester, M.D.
- Independent Director
- 442.59K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data